146 related articles for article (PubMed ID: 36290898)
21. Ablative dose stereotactic body radiation therapy for oligometastatic disease: a prospective single institution study.
Burkon P; Kazda T; Pospisil P; Slavik M; Kominek L; Selingerova I; Blakaj DM; Prochazka T; Vrzal M; Rehak Z; Slampa P
Neoplasma; 2019 Mar; 66(2):315-325. PubMed ID: 30509112
[TBL] [Abstract][Full Text] [Related]
22. Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases.
Goodman BD; Mannina EM; Althouse SK; Maluccio MA; Cárdenes HR
Pract Radiat Oncol; 2016; 6(2):86-95. PubMed ID: 26725957
[TBL] [Abstract][Full Text] [Related]
23. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
Rieber J; Streblow J; Uhlmann L; Flentje M; Duma M; Ernst I; Blanck O; Wittig A; Boda-Heggemann J; Krempien R; Lohaus F; Klass ND; Eble MJ; Imhoff D; Kahl H; Petersen C; Gerum S; Henkenberens C; Adebahr S; Hass P; Schrade E; Wendt TG; Hildebrandt G; Andratschke N; Sterzing F; Guckenberger M
Lung Cancer; 2016 Jul; 97():51-8. PubMed ID: 27237028
[TBL] [Abstract][Full Text] [Related]
24. 30 Gy single dose stereotactic body radiation therapy (SBRT): Report on outcome in a large series of patients with lung oligometastatic disease.
Osti MF; Agolli L; Valeriani M; Reverberi C; Bracci S; Marinelli L; De Sanctis V; Cortesi E; Martelli M; De Dominicis C; Minniti G; Nicosia L
Lung Cancer; 2018 Aug; 122():165-170. PubMed ID: 30032826
[TBL] [Abstract][Full Text] [Related]
25. Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy.
Franzese C; Comito T; Franceschini D; Loi M; Clerici E; Navarria P; De Rose F; Di Brina L; Mancosu P; Reggiori G; Tomatis S; Scorsetti M
J Cancer Res Clin Oncol; 2020 May; 146(5):1227-1234. PubMed ID: 32056005
[TBL] [Abstract][Full Text] [Related]
26. Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: Some patients survive longer than a decade.
Milano MT; Katz AW; Zhang H; Huggins CF; Aujla KS; Okunieff P
Radiother Oncol; 2019 Feb; 131():45-51. PubMed ID: 30773186
[TBL] [Abstract][Full Text] [Related]
27. Stereotactic body radiation therapy for liver oligometastases: predictive factors of local response by
Mazzola R; Fersino S; Alongi P; Di Paola G; Gregucci F; Aiello D; Tebano U; Pasetto S; Ruggieri R; Salgarello M; Alongi F
Br J Radiol; 2018 Jul; 91(1088):20180058. PubMed ID: 29750538
[TBL] [Abstract][Full Text] [Related]
28. MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial.
Hoegen P; Zhang KS; Tonndorf-Martini E; Weykamp F; Regnery S; Naumann P; Lang K; Ristau J; Körber SA; Dreher C; Buchele C; Rippke C; Renkamp CK; Paul KM; König L; Büsch C; Krisam J; Sedlaczek O; Schlemmer HP; Niyazi M; Corradini S; Debus J; Klüter S; Hörner-Rieber J
Radiat Oncol; 2022 Mar; 17(1):59. PubMed ID: 35346270
[TBL] [Abstract][Full Text] [Related]
29. Stereotactic body radiation therapy in the treatment of cancer patients with oligometastatic disease: a real world study.
Stefanovic M; Calvet G; Pérez-Montero H; Esteve A; Bujalance MV; Navarro-Martín A; Fernández MDA; González FF; Borras SM; Borbalas AL; Fernandez MN; Garau MM; Calduch AL; Edo FG
Clin Transl Oncol; 2023 Jan; 25(1):199-206. PubMed ID: 36068449
[TBL] [Abstract][Full Text] [Related]
30. Stereotactic body radiation therapy for extracranial oligometastases: does the sword have a double edge?
Carey Sampson M; Katz A; Constine LS
Semin Radiat Oncol; 2006 Apr; 16(2):67-76. PubMed ID: 16564442
[TBL] [Abstract][Full Text] [Related]
31. Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases.
Al-Hallaq HA; Chmura S; Salama JK; Winter KA; Robinson CG; Pisansky TM; Borges V; Lowenstein JR; McNulty S; Galvin JM; Followill DS; Timmerman RD; White JR; Xiao Y; Matuszak MM
Pract Radiat Oncol; 2016; 6(6):e291-e298. PubMed ID: 27345129
[TBL] [Abstract][Full Text] [Related]
32. Stereotactic Body Radiation Therapy for Mediastinal and Hilar Lymph Node Metastases.
Shahi J; Poon I; Ung YC; Tsao M; Bjarnason GA; Malik NH; Zhang L; Louie AV; Cheung P
Int J Radiat Oncol Biol Phys; 2021 Mar; 109(3):764-774. PubMed ID: 33115687
[TBL] [Abstract][Full Text] [Related]
33. Oligometastatic breast cancer: where are we now and where are we headed?-a narrative review.
Kent CL; McDuff SGR; Salama JK
Ann Palliat Med; 2021 May; 10(5):5954-5968. PubMed ID: 32921069
[TBL] [Abstract][Full Text] [Related]
34. Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases.
Nicosia L; Cuccia F; Mazzola R; Figlia V; Giaj-Levra N; Ricchetti F; Rigo M; Bonù M; Corradini S; Tolia M; Alongi F
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2351-2358. PubMed ID: 32356176
[TBL] [Abstract][Full Text] [Related]
35. 5-year results of accelerated partial breast irradiation (APBI) with SBRT (stereotactic body radiation therapy) and exactrac adaptive gating (Novalis
Ciérvide R; Montero Á; Potdevin G; García J; Aranda MG; Álvarez B; Rossi K; López M; Hernando O; Valero J; Sánchez E; Chen X; Alonso R; Letón PF; Rubio C
Clin Transl Oncol; 2021 Nov; 23(11):2358-2367. PubMed ID: 34043153
[TBL] [Abstract][Full Text] [Related]
36. Stereotactic radiotherapy in oligoprogressive and oligorecurrent urothelial cancer patients: A retrospective experience.
Francolini G; Desideri I; Detti B; Di Cataldo V; Masi L; Caramia G; Visani L; Terziani F; Muntoni C; Lo Russo M; Loi M; Livi L
Cancer Treat Res Commun; 2019; 19():100124. PubMed ID: 30851645
[TBL] [Abstract][Full Text] [Related]
37. Phase 2 Study of Stereotactic Body Radiation Therapy for Patients with Oligometastatic Esophageal Squamous Cell Carcinoma.
Liu Q; Zhu Z; Chen Y; Deng J; Ai D; Liu Q; Wang S; Wu S; Chen J; Zhao K
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):707-715. PubMed ID: 32417405
[TBL] [Abstract][Full Text] [Related]
38. Stereotactic body radiotherapy (SBRT) and concomitant systemic therapy in oligoprogressive breast cancer patients.
Nicosia L; Figlia V; Ricottone N; Cuccia F; Mazzola R; Giaj-Levra N; Ricchetti F; Rigo M; Jafari F; Maria Magrini S; Girlando A; Alongi F
Clin Exp Metastasis; 2022 Aug; 39(4):581-588. PubMed ID: 35511313
[TBL] [Abstract][Full Text] [Related]
39. Oligometastases: history of a hypothesis.
Milano MT; Biswas T; Simone CB; Lo SS
Ann Palliat Med; 2021 May; 10(5):5923-5930. PubMed ID: 32279519
[TBL] [Abstract][Full Text] [Related]
40. Liver Metastases-directed Therapy in the Management of Oligometastatic Breast Cancer.
Franzese C; Comito T; Viganò L; Pedicini V; Franceschini D; Clerici E; Loi M; Donadon M; Poretti D; Solbiati L; Torzilli G; Scorsetti M
Clin Breast Cancer; 2020 Dec; 20(6):480-486. PubMed ID: 32631769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
